The microbiota-metabolite-immune axis in the olfactory cleft microenvironment: mechanisms and therapeutic implications for dysbiosis-driven olfactory dysfunction in chronic rhinosinusitis - Summary - MDSpire
Advertisement
The microbiota-metabolite-immune axis in the olfactory cleft microenvironment: mechanisms and therapeutic implications for dysbiosis-driven olfactory dysfunction in chronic rhinosinusitis
To propose the microbiota-metabolite-immune (MMI) axis as a framework linking microbial dysbiosis, metabolite perturbation, and immune remodeling in chronic rhinosinusitis (CRS)-associated olfactory dysfunction.
Approach:
Microbial Dysbiosis: Examined studies reporting dysbiosis in the olfactory niche, including the enrichment of Acinetobacter johnsonii and depletion of commensals.
Metabolite Profiles: Analyzed altered metabolite profiles in CRS-OD associated with disturbed purine metabolism and reduced protective metabolites.
Immune Remodeling: Investigated the role of Staphylococcus aureus superantigens in promoting Th2 polarization and disrupting olfactory neurogenesis.
Therapeutic Strategies: Explored microbiota-targeted therapeutics such as xylitol irrigation, probiotics, and IL-4Rα blockade.
Key Findings:
Dysbiosis in the olfactory niche is linked to olfactory dysfunction in CRS.
Altered metabolite profiles contribute to innate inflammatory signaling.
Staphylococcus aureus superantigens may impair olfactory neurogenesis.
The MMI axis provides a framework for understanding CRS-associated olfactory dysfunction and highlights the need for further research to establish causal relationships.
Limitations:
Current evidence is predominantly associative rather than mechanistic.
Research gaps exist in understanding the specific roles of microbial and metabolic disturbances.
Conclusion:
The MMI axis framework enhances the understanding of CRS-associated olfactory dysfunction and identifies potential therapeutic targets.
IBTV speaks with industry leaders at ARM’s Meeting on the Med 2026 to explore what recent clinical, regulatory, and commercial milestones reveal about the next phase of cell and gene therapy
Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.
